ArticleAdvanced biomedical research2023
Evaluation of Two-Year Follow-Up of Patients with BI-RADS 3 Breast Ultrasound Lesions in a Single Private Ultrasound Study.
Article in Advanced biomedical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Automated breast ultrasound (ABUS) meets artificial intelligence: a new accurate classification tool for BIRADS 3-4 breast lesions.Journal of ultrasound · 2026Article
- Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).Breast cancer research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assessed the frequency and progression rate of BI-RADS 4 or BI-RADS 2 during a two-year follow-up of patients with BI-RADS 3 on ultrasound screening. Materials and Methods: This descriptive cross-sectional study was conducted on patients with BI-RADS 3 lesions who entered to study from 2013 to 2018 and underwent an ultrasound on the months of 6 Results: The study included six hundred-four patients with BI-RADS 3 lesions at baseline. Participants' mean ± SD (median, min-max) age was 413 ± 9.7 (40, 19-75). By month 24, BI-RADS 3 changed to BI-RADS 2 in 585 (96.6%) and BI-RADS 4 in 19 (3.1%) cases.Considering the size of breast lesions, the breast sensitivity and specificity for predicting size progression and changing to BI-RADS 4 were as follows: For long axis diameter, 12 mm at baseline with 72.22% sensitivity and specificity of 71.53% and 16 mm in 6 months follow-up with sensitivity of 75% and specificity of 83.78%.For short axis diameter, 6 mm at baseline with a sensitivity of 83.33% and specificity of 62.89% and 8 mm in 6 months follow-up with a sensitivity of 66.67% and specificity of 83.48%. Conclusion: The breast lesion size was the most crucial factor in altering the BI-RADS 3 to 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.